Search Results - "CLAUSSEN, Lori R"

Pulmonary vascular input impedance is a combined measure of pulmonary vascular resistance and stiffness and predicts clinical outcomes better than pulmonary vascular resistance alone in pediatric patients with pulmonary hypertension by Hunter, Kendall S., PhD, Lee, Po-Feng, MSc, Lanning, Craig J., BSc, Ivy, D. Dunbar, MD, Kirby, K. Scott, RDCS, Claussen, Lori R., BSN, RN, Chan, K. Chen, MD, Shandas, Robin, PhD

“…Background Pulmonary vascular resistance (PVR) is the current standard for evaluating reactivity in children with pulmonary arterial hypertension (PAH)…”
Get full text

Effects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension by Rosenzweig, Erika Berman, Ivy, D. Dunbar, Widlitz, Allison, Doran, Aimee, Claussen, Lori R., Yung, Delphine, Abman, Steven H., Morganti, Adele, Nguyen, Ngoc, Barst, Robyn J.

“…This study investigated the long-term outcome of children with pulmonary arterial hypertension (PAH) treated with bosentan therapy, with or without concomitant…”
Get full text

Short- and Long-Term Effects of Inhaled Iloprost Therapy in Children With Pulmonary Arterial Hypertension by Ivy, D. Dunbar, MD, Doran, Aimee K., CPNP, Smith, Kelly J., MD, Mallory, George B., MD, Beghetti, Maurice, MD, Barst, Robyn J., MD, Brady, Daniela, RN, Law, Yuk, MD, Parker, Donna, RRT, Claussen, Lori, RN, Abman, Steven H., MD

“…Short- and Long-Term Effects of Inhaled Iloprost Therapy in Children With Pulmonary Arterial Hypertension D. Dunbar Ivy, Aimee K. Doran, Kelly J. Smith, George…”
Get full text

Pulmonary Vascular Input Impedance is a Combined Measure of Pulmonary Vascular Resistance and Stiffness and Predicts Clinical Outcomes Better than PVR Alone in Pediatric Patients with Pulmonary Hypertension by Hunter, Kendall S., Lee, Po-Feng, Lanning, Craig J., Ivy, D. Dunbar, Kirby, K. Scott, Claussen, Lori R., Chan, K. Chen, Shandas, Robin

Get full text

Reply by Rosenzweig, Erika Berman, Ivy, D Dunbar, Widlitz, Allison, Doran, Aimee, Claussen, Lori R, Yung, Delphine, Abman, Steven H, Barst, Robyn J

“…[...]dissolution rates were measured and found to be similar for both whole and halved tablets. [...]the use of split tablets was considered appropriate for…”
Get full text

Reply by Rosenzweig, Erika Berman, Ivy, D. Dunbar, Widlitz, Allison, Doran, Aimee, Claussen, Lori R., Yung, Delphine, Abman, Steven H., Barst, Robyn J.

Get full text

Effects of long-term bosentan in children with pulmonary arterial hypertension. Commentary by ROSENZWEIG, Erika Berman, IVY, D. Dunbar, ADATIA, Ian, WIDLITZ, Allison, DORAN, Aimee, CLAUSSEN, Lori R, YUNG, Delphine, ABMAN, Steven H, MORGANTI, Adele, NGUYEN, Ngoc, BARST, Robyn J

Get full text

Transition of Stable Pediatric Patients With Pulmonary Arterial Hypertension from Intravenous Epoprostenol to Intravenous Treprostinil by Ivy, D. Dunbar, MD, Claussen, Lori, BSN, RN, Doran, Aimee, MS, RN, CPNP

“…Intravenous epoprostenol was the first agent approved by the United States Food and Drug Administration for the management of pulmonary arterial hypertension…”
Get full text